prikaz prve stranice dokumenta Diclofenac sodium versus ceftazidime for preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a prospective, randomized, controlled trial.
Rad je dostupan svim korisnicima iz sustava znanosti i visokog obrazovanja RH
Znanstveni rad - Izvorni znanstveni rad
Diclofenac sodium versus ceftazidime for preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a prospective, randomized, controlled trial.
Surgical endoscopy, 31 (2017); 602-610. https://doi.org/10.1007/s00464-016-5004-9
Hauser, Goran; Blažević, Ivana; Salkić, Nermin; Poropat, Goran; Giljača, Vanja; Bulić, Zlatko; Štimac, Davor

Citirajte ovaj rad

Hauser, G., Blažević, I., Salkić, N., Poropat, G., Giljača, V., Bulić, Z. i Štimac, D. (2017). Diclofenac sodium versus ceftazidime for preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a prospective, randomized, controlled trial.. Surgical endoscopy, 31., 602-610. doi: 10.1007/s00464-016-5004-9

Hauser, Goran, et al. "Diclofenac sodium versus ceftazidime for preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a prospective, randomized, controlled trial.." Surgical endoscopy, vol. 31, 2017, str. 602-610. https://doi.org/10.1007/s00464-016-5004-9

Hauser, Goran, Ivana Blažević, Nermin Salkić, Goran Poropat, Vanja Giljača, Zlatko Bulić i Davor Štimac. "Diclofenac sodium versus ceftazidime for preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a prospective, randomized, controlled trial.." Surgical endoscopy 31 (2017): 602-610. https://doi.org/10.1007/s00464-016-5004-9

Hauser, G., et al. (2017) 'Diclofenac sodium versus ceftazidime for preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a prospective, randomized, controlled trial.', Surgical endoscopy, 31, str. 602-610. doi: 10.1007/s00464-016-5004-9

Hauser G, Blažević I, Salkić N, Poropat G, Giljača V, Bulić Z, i sur.. Diclofenac sodium versus ceftazidime for preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a prospective, randomized, controlled trial.. Surgical endoscopy [Internet]. 2017. [pristupljeno 13.04.2024.];31:602-610. doi: 10.1007/s00464-016-5004-9

G. Hauser, et al., "Diclofenac sodium versus ceftazidime for preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a prospective, randomized, controlled trial.", Surgical endoscopy, vol. 31, str. 602-610, 2017. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:430409. [Citirano: 13.04.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:430409
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Diclofenac sodium versus ceftazidime for preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a prospective, randomized, controlled trial.
AutorGoran Hauser
AutorIvana Blažević
AutorNermin Salkić
AutorGoran Poropat
AutorVanja Giljača
AutorZlatko Bulić
AutorDavor Štimac
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za internu medicinu)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Background and Aims: We aimed to compare the efficacy of prophylactic, parenterally administered ceftazidime and rectally applied diclofenac sodium for the prophylaxis of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP). Methods: We prospectively enrolled patients who underwent ERCP. In a doubleblinded randomized controlled trial, patients received a suppository containing diclofenac sodium rectally (100 mg) and placebo intravenously (group A) or ceftazidime intravenously (1 g) and placebo rectally (group B) immediately before the procedure. The serum and urine amylase levels were recorded and the patients were clinically evaluated after ERCP. Results: Of the 272 patients enrolled (group A: 129 ; group B: 143), 32 developed pancreatitis (group A: 11 [8.5%] ; group B: 21 [14.7%] ; P = 0.17 ; relative risk = 1.72 ; 95% confidence interval [CI] = 0.86-3.43). The severity of the pancreatitis or complications did not significantly differ between the groups. A serum amylase level of ≥ 560 U/L and urine amylase level of ≥ 1150 U/L indicated a positive likelihood ratio for post-ERCP pancreatitis of ≥ 10. Moreover, the threshold visual analog scale score of ≤ 5 for abdominal pain after ERCP had excellent diagnostic potential for predicting the presence or absence of post-ERCP pancreatitis. Conclusions: The PEP incidence did not differ between the ceftazidime and diclofenac sodium groups. In patients with nonsteroidal anti-inflammatory drug contraindications, antibiotics can be considered a safe alternative to diclofenac sodium for PEP prevention. Moreover, the visual analog scale for abdominal pain has excellent diagnostic value for predicting PEP. Clinical trials.gov number, NCT 01784445.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaSurgical endoscopy
Brojčani podacivol. 31, str. 602-610
p-ISSN0930-2794
DOIhttps://doi.org/10.1007/s00464-016-5004-9
URN:NBNurn:nbn:hr:184:430409
Datum objave publikacije2017
ProjektŠifra: 13.06.1.2.30
Naziv (hrvatski): Antimikrobna profilaksa u liječenju bolesnika s akutnim pankreatitisom
Voditelj: Davor Štimac
Pravna nadležnost: Hrvatska
Financijer: NadSve
Linija financiranja: Sveučilište u Rijeci
URL dokumentahttp://bib.irb.hr/913175
Vrsta resursaTekst
Prava pristupaOgraničen pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2022-02-16 16:46:35